iNtRON Biotechnology Inc (048530) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.013x

Based on the latest financial reports, iNtRON Biotechnology Inc (048530) has a cash flow conversion efficiency ratio of -0.013x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-993.53 Million ≈ $-673.30K USD) by net assets (₩73.98 Billion ≈ $50.13 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See iNtRON Biotechnology Inc balance sheet independence to measure how much of total assets are equity-financed.

iNtRON Biotechnology Inc - Cash Flow Conversion Efficiency Trend (2012–2024)

This chart illustrates how iNtRON Biotechnology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check iNtRON Biotechnology Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

iNtRON Biotechnology Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of iNtRON Biotechnology Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Solidion Technology Inc. NASDAQ:STI	0.017x
Wisekey International Holding AG SW:WIHN	-0.070x
XCF Global, Inc. Class A Common Stock NASDAQ:SAFX	-1.000x
Y-Optics Manufacture Co. Ltd KQ:066430	-0.022x
Global Education Limited NSE:GLOBAL	0.078x
Neo-Concept International Group Holdings Limited Ordinary Shares NASDAQ:NCI	0.008x
Bactiguard Holding AB (publ) ST:BACTI-B	-0.024x
LEFORM KLSE:0266	0.111x

Annual Cash Flow Conversion Efficiency for iNtRON Biotechnology Inc (2012–2024)

The table below shows the annual cash flow conversion efficiency of iNtRON Biotechnology Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see iNtRON Biotechnology Inc market cap and net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩83.77 Billion ≈ $56.77 Million	₩-138.47 Million ≈ $-93.84K	-0.002x	-105.13%
2023-12-31	₩96.73 Billion ≈ $65.56 Million	₩3.12 Billion ≈ $2.11 Million	0.032x	-42.74%
2022-12-31	₩106.18 Billion ≈ $71.96 Million	₩5.98 Billion ≈ $4.05 Million	0.056x	-65.37%
2021-12-31	₩101.35 Billion ≈ $68.68 Million	₩16.47 Billion ≈ $11.16 Million	0.163x	+94.60%
2020-12-31	₩85.38 Billion ≈ $57.86 Million	₩7.13 Billion ≈ $4.83 Million	0.084x	+767.82%
2019-12-31	₩64.96 Billion ≈ $44.02 Million	₩-812.48 Million ≈ $-550.61K	-0.013x	-111.64%
2018-12-31	₩39.09 Billion ≈ $26.49 Million	₩4.20 Billion ≈ $2.85 Million	0.107x	+159.44%
2017-12-31	₩30.24 Billion ≈ $20.50 Million	₩-5.47 Billion ≈ $-3.71 Million	-0.181x	-91.32%
2016-12-31	₩49.15 Billion ≈ $33.31 Million	₩-4.64 Billion ≈ $-3.15 Million	-0.094x	-291.53%
2015-12-31	₩34.44 Billion ≈ $23.34 Million	₩1.70 Billion ≈ $1.15 Million	0.049x	+277.79%
2012-12-31	₩11.93 Billion ≈ $8.08 Million	₩-331.01 Million ≈ $-224.32K	-0.028x	--

About iNtRON Biotechnology Inc

KQ:048530 Korea Biotechnology

Market Cap

$55.81 Million

₩82.35 Billion KRW

Market Cap Rank

#21432 Global

#1228 in Korea

Share Price

₩2605.00

Change (1 day)

+6.98%

52-Week Range

₩2330.00 - ₩6650.00

All Time High

₩46250.00